Indivior Plc

Indivior Plc

INDV

Get informed when a big investor buys or sells

+ Follow
Market Cap$4.69B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Indivior PlcIndivior Plc18.8--175%3.8-0.4
$-1.19

Current Fair Value

103.1% downside

Overvalued by 103.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$4.69 Billion
Enterprise Value$4.58 Billion
Dividend Yield$- (-)
Earnings per Share$1.68
Beta1.2
Outstanding Shares125,352,000

Return

Return on Equity-175.00%ROE
Return on Assets21.05%
Return on Invested Capital81.10%

Valuation & Multiples

P/E Ratio18.79P/E Ratio
PEG21.02PEG
Price to Sales3.85Price to Sales
Price to Book Ratio-19.24Price to Book Ratio
Enterprise Value to Revenue3.55
Enterprise Value to EBIT13.51
Enterprise Value to Net Income18
Total Debt to Enterprise0.01
Debt to Equity-0.44Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
April 30, 2026
EPS Estimate
$0.64
Average shareholder expectation
Revenue Estimate
$272.84 M
Average shareholder expectation

Next Earnings Call

Expected Date
July 30, 2026
EPS Estimate
$0.88
Average shareholder expectation
Revenue Estimate
$306.55 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.8729 83.26%
Total Calls310,900 85.00%
Total Puts271,400 224.25%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %102.18% 11.73%
Total Invested$3.89B 4.00%
Investors Holding296 39.00%

ESG Score

No data

About Indivior Plc

CEO: Shaun Thaxter

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...